Shire Expects Vyvanse Decision By March – CEO Emmens
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Shire anticipates FDA approval of its next-generation attention deficit/hyperactivity disorder treatment Vyvanse (lisdexamfetamine dimesylate) within the next couple of months, Shire CEO Matthew Emmens said Jan. 3